Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trial.

Int J Gynecol CancerJun 19, 2026 (epub)
Clinical ResearchOncology (Medical)

Vanda Salutari, Claudia Marchetti, Elena Giudice et al.

✦ AI-curated · Sources linked

In 30 seconds

The NUVOLA trial, a phase II open-label study, evaluated the addition of olaparib to neoadjuvant chemotherapy in 36 patients with BRCA-mutated advanced epithelial ovarian cancer. The study found a complete pathological response in 8.6% of patients, suggesting that concurrent use of olaparib does not enhance the efficacy of platinum-based chemotherapy in this setting.

Key findings

  • Complete pathological response was achieved in 8.6% of patients.
  • The overall response rate was 89% at the end of neoadjuvant treatment.
  • Median progression-free survival was 39.7 months.
  • 86% of patients experienced treatment-related adverse events.

Why it matters

Understanding the efficacy of concurrent olaparib with chemotherapy is crucial for optimizing treatment strategies in BRCA-mutated ovarian cancer, as it may influence future therapeutic approaches and patient management.

Source

PubMed · PMID 42435644

Published in Int J Gynecol Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.